<DOC>
	<DOCNO>NCT02095314</DOCNO>
	<brief_summary>Measure antibody persistence prior booster administration Pentabio vaccine .</brief_summary>
	<brief_title>Antibody Persistence , Immune Response Safety After Doses Pentabio Vaccine</brief_title>
	<detailed_description>Number percentage child anti diphtheria , titer anti tetanus titer &gt; = 0.01 IU/ml , anti HBs &gt; =10mIU/ml , anti Hib &gt; =0.15ug/ml prior booster administration .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Children , 1824 month age Subjects complete primary series Pentabio vaccine previous trial Father , mother , legally acceptable representative inform properly regard study sign informed consent form Subject 's parent commit comply instruction Subjects concomitantly enrol schedule enrol another trial Evolving mild , moderate severe illness , especially infectious disease fever ( axillary temperature &gt; =37.5oC Day 0 ) Known history uncontrolled coagulopathy blood disorder contraindicate intramuscular injection Known history allergy component vaccine ( e.f. formaldehyde ) Known history acquire immunodeficiency ( include HIV infection ) Subject receive treatment likely alter immune response previous 4 week ( e.g intravenous immunoglobulin , bloodderived product long term corticotherapy ( &gt; 2 week ) Subject receive vaccination within 1 month prior inclusion Any abnormality chronic disease justify investigator might interfere assessment trial objective Infant know history diphtheria , tetanus , pertussis , Hepatitis B Hib infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>DTP-HB-Hib</keyword>
	<keyword>Pentavalen</keyword>
	<keyword>Pentabio</keyword>
	<keyword>Booster</keyword>
</DOC>